Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO‐HOPE

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Diabetes/Metabolism Research Reviews

• Publication date

  2002-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/dmrr.285PMID 12324991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical trials report

  2001cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

  2000influential reference
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Vitamin E supplementation and cardiovascular events in high-risk patients.

  2000cited by this paper
• Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study.

  1993cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper
• Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

  1992cited by this paper
• A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women.

  1991cited by this paper
• Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.

  1991cited by this paper
• Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.

  1991cited by this paper
• Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study.

  1983cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper

• Impact of Angiotensin‐Converting Enzyme Inhibitor on Coronary Artery Calcification Evaluated by Intravascular Ultrasound: A Retrospective Cohort Study

  2025cites this paper
• Inhibition of the Renin–Angiotensin System Improves Hemodynamic Function of the Diabetic Rat Heart by Restoring Intracellular Calcium Regulation

  2025influential citation
• Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies

  2024cites this paper
• Prescribing Trends of Renin-Angiotensin System Inhibitors and Mortality among Acute Coronary Syndrome Patients: Insights from the Malaysian National Cardiovascular Disease Registry

  2024cites this paper
• The role of the albumin-to-creatinine ratio in the diagnosis of diabetic kidney disease (literature review and own findings)

  2023cites this paper
• Association of Non-Dipping Blood Pressure Patterns with Diabetic Peripheral Neuropathy: A Cross-Sectional Study among a Population with Diabetes in Greece

  2022cites this paper
• Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction

  2021cites this paper
• Антиоксидантная терапия последствий ишемических инсультов, с позиции доказательной медицины

  2020cites this paper
• Efficiency (advantages) of ramipril in arterial hypertension and diabetes mellitus from the point of view of evidence-based medicine

  2020cites this paper
• Initiator Types and the Causal Question of the Prevalent New User Design: A Simulation Study.

  2020cites this paper
• A randomised controlled trial of potential for pharmacologic prevention of new-onset albuminuria, hypertension and diabetes in a remote Aboriginal Australian community, 2008–2013

  2019influential citation
• Predominant Complications of Type 2 Diabetes in Kumasi: A 4-Year Retrospective Cross-Sectional Study at a Teaching Hospital in Ghana

  2019cites this paper
• Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control

  2018cites this paper
• Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010–2015

  2018cites this paper
• An eBook on Type 2 Diabetes

  2018cites this paper
• Ataque isquémico transitorio y riesgo de trombosis cerebral en pacientes con diabetes: prevención y tratamiento Transient ischemic attack and risk of stroke in patients with diabetes: prevention and treatment

  2016cites this paper
• [Effect of Antihypertensive Drugs on Regression of Left Ventricular Hypertrophy].

  2015cites this paper
• Identifying Common Genetic Risk Factors of Diabetic Neuropathies

  2015cites this paper
• Willingness to take drugs to prevent serious chronic diseases (自愿服用药物以预防严重的慢性疾病)

  2014cites this paper
• Effects of Sub therapeutic Doses of ACE-I in Improving insulin sensitivity in Type II DM Patients

  2014cites this paper
• [The role of ramipril in the therapy of diabetic nephropathy].

  2014cites this paper
• Cell type specific mechanisms of mineralocorticoid receptor mediated renal injury

  2014cites this paper
• A ramipril helye a diabeteses nephropathia terápiájában

  2014cites this paper
• In vivo and in vitro evidence of the sex-dependent pharmacokinetics and disposition of G004, a potential hypoglycemic agent, in rats

  2014cites this paper
• Current Clinical Status and Vascular Complications among Patients with Type 2 Diabetes Mellitus at Tertiary Hospitals in Malaysia

  2014cites this paper
• [Analysis of the effect of antihypertensive drugs on left ventricular hypertrophy regression].

  2014cites this paper
• KNOWLEDGE ON DIABETES AMONG ADULTS IN THE

  2014cites this paper
• An evaluation of a self-management package for people with diabetes at risk of chronic kidney disease

  2013cites this paper
• Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.

  2013cites this paper
• The Effect of Salvia Hispanica L. Seeds on Weight Loss in Overweight and Obese Individuals with Type 2 Diabetes Mellitus

  2013cites this paper
• Building Capacity to Reduce Disparities in Diabetes

  2012cites this paper
• The therapeutic effects of the combined use of American ginseng (Panax quinquefolius L.) extract and Korean red ginseng (Panax Ginseng C.A. Meyer) extract in the management of type 2 diabetes mellitus and cardiovascular risk factors

  2012cites this paper
• Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

  2012cites this paper
• Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System

  2012cites this paper
• Reducing cardiovascular risk factors in patients with prediabetes REVIEW

  2011cites this paper
• Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis

  2011cites this paper
• Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk: Results From the ONTARGET and TRANSCEND Studies

  2011cites this paper
• Reducing cardiovascular risk factors in patients with prediabetes

  2011cites this paper
• The development and evaluation of a self-management package for people with diabetes at risk of chronic kidney disease

  2010cites this paper
• Transient ischemic attack and risk of stroke in patients with diabetes: prevention and treatment Ataque isquémico transitorio y riesgo de trombosis cerebral en pacientes con diabetes: prevención y tratamiento

  2010cites this paper
• Ataque isquémico transitorio riesgo de trombosis cerebral en pacientes con diabetes: prevención tratamiento

  2010cites this paper
• Evaluation of cardiovascular risk assessment models with respect to the clinical interpretation of atherosclerosis in a different type II diabetes cohort

  2009cites this paper
• An Interactive Telehealth Program to Improve Attitudes Toward Treating Diabetes

  2009cites this paper
• Diabetes and cardiovascular disease prevention in older adults.

  2009cites this paper
• Микроальбуминурия — диагностическое и прогностическое значение при артериальной гипертонии

  2009cites this paper
• Macrovascular and Microvascular Complications

  2009cites this paper
• Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus.

  2008cites this paper
• Blood pressure control and prevention of stroke in adults with diabetes

  2008cites this paper
• KAPITEL 6 – Diabetische Nephropathie

  2008cites this paper
• Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-tThe Hong Kong Diabetes Registry.

  2008cites this paper
• Antioxidant supplements for preventing gastrointestinal cancers.

  2008cites this paper
• Different types of renal dysfunction in patients with acute myocardial infarction treated with percutaneous coronary intervention.

  2007cites this paper
• Prevention and treatment of obesity with lifestyle interventions: review and meta-analysis

  2007cites this paper
• Treating the metabolic syndrome

  2007cites this paper
• Assessment of the Patient With Diabetes for Coronary Heart Disease Risk: Review and Personal Reflection

  2007cites this paper
• Quality of care indicators, health behaviors, and physical functioning in adults with diabetes.

  2007cites this paper
• Future strategies for improving outcomes in patients with diabetes and acute coronary syndromes.

  2007cites this paper
• Setting up chronic disease programs: perspectives from Aboriginal Australia.

  2006cites this paper
• Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.

  2006cites this paper
• Combined treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARB): 'Beating a dead horse' or meaningful mechanism-guided therapy?

  2006cites this paper
• Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2006cites this paper
• Clinical decision-making in blood pressure management of patients with diabetes mellitus: an Oklahoma Physicians Resource/Research Network (OKPRN) Study.

  2006cites this paper
• Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulären System

  2006cites this paper
• The New Endocrinologist

  2006cites this paper
• Aspectos endocrinos, metabólicos y genéticos de la disfunción endotelial y su relación con la obesidad visceral

  2005cites this paper
• Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver

  2005cites this paper
• Proteinuria reduction: Mandatory consideration or option when selecting an antihypertensive agent?

  2005cites this paper
• Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

  2005cites this paper
• Hypertension treatment guidelines: practical implications.

  2005cites this paper
• Tolerability of Ramipril 10 mg Daily in High‐risk Cardiovascular Patients in Taiwan: Experience from Kaohsiung Medical University Chung‐Ho Memorial Hospital

  2005cites this paper
• Treatment Guidelines : ractical Implications enneth

  2005cites this paper
• Therapeutic Interventions to Improve Endothelial Function in Diabetes

  2005cites this paper
• Grado de control de la presión arterial en un grupo de pacientes con diabetes mellitus tipo 2

  2005influential citation
• Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.

  2005cites this paper
• Grado de control de la presión arterial en un grupo de pacientes con diabetes mellitus tipo 2

  2005influential citation
• Transient ischemic attacks: Part II. Treatment.

  2004cites this paper
• Inhibitors of the RAS: Evidence-Based Medicine

  2004cites this paper
• Preventing Type II Diabetes Mellitus

  2004cites this paper
• Insulin resistance and hypertension.

  2004cites this paper
• The Rationale for Early , Aggressive Treatment of Type 2 Diabetes : The Cost Ramifications of Improved Health Outcomes

  2004cites this paper
• Diabetic nephropathy and retinopathy.

  2004cites this paper
• Neurohormonal mechanisms in insulin resistance and type 2 diabetes

  2004cites this paper
• Reaktive Sauerstoffspezies als Ursache der endothelialen Dysfunktion im Diabetes

  2004cites this paper
• Was leisten ACE-Hemmer und AT1-Antagonisten jenseits der Blutdrucksenkung?

  2004cites this paper
• Protection rénale: données récentes en faveur d’une nouvelle approche — l’étude PREMIER

  2004cites this paper
• Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines?

  2004cites this paper
• Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.

  2004cites this paper
• Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system

  2004cites this paper
• Antioxidant supplements for preventing gastrointestinal cancers.

  2004cites this paper
• VARIATIONS IN STROKE INCIDENCE IN FOUR US COMMUNITIES: THE CARDIOVASCULAR HEALTH STUDY (CHS)

  2004cites this paper
• The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme

  2003cites this paper
• Drug Therapy for Hypertension: Does ALLHAT Alter our Approach?

  2003cites this paper
• Prospective Medicine: The Next Health Care Transformation

  2003cites this paper
• Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.

  2003cites this paper
• New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.

  2003cites this paper
• Prevention of type 2 diabetes

  2003cites this paper
• Insulin resistance: a global epidemic in need of effective therapies

  2003cites this paper